Tags

Type your tag names separated by a space and hit enter

The neuroprotective effects of caffeine: a prospective population study (the Three City Study).
Neurology. 2007 Aug 07; 69(6):536-45.Neur

Abstract

OBJECTIVE

To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over.

METHODS

Participants were 4,197 women and 2,820 men from a population-based cohort recruited from three French cities. Cognitive performance, clinical diagnosis of dementia, and caffeine consumption were evaluated at baseline and at 2 and 4 year follow-up.

RESULTS

Caffeine consumption is associated with a wide range of sociodemographic, lifestyle, and clinical variables which may also affect cognitive decline. Multivariate mixed models and multivariate adjusted logistic regression indicated that women with high rates of caffeine consumption (over three cups per day) showed less decline in verbal retrieval (OR = 0.67, CI = 0.53, 0.85), and to a lesser extent in visuospatial memory (OR = 0.82, CI = 0.65, 1.03) over 4 years than women consuming one cup or less. The protective effect of caffeine was observed to increase with age (OR = 0.73, CI = 0.53, 1.02 in the age range 65 to 74; OR = 0.3, CI = 0.14, 0.63 in the range 80+). No relation was found between caffeine intake and cognitive decline in men. Caffeine consumption did not reduce dementia risk over 4 years.

CONCLUSIONS

The psychostimulant properties of caffeine appear to reduce cognitive decline in women without dementia, especially at higher ages. Although no impact is observed on dementia incidence, further studies are required to ascertain whether caffeine may nonetheless be of potential use in prolonging the period of mild cognitive impairment in women prior to a diagnosis of dementia.

Authors+Show Affiliations

INSERM U888 Nervous System Pathologies, Epidemiological and Clinical Research, La Colombière Hospital, Montpellier, France. ritchie@montp.inserm.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17679672

Citation

Ritchie, K, et al. "The Neuroprotective Effects of Caffeine: a Prospective Population Study (the Three City Study)." Neurology, vol. 69, no. 6, 2007, pp. 536-45.
Ritchie K, Carrière I, de Mendonca A, et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology. 2007;69(6):536-45.
Ritchie, K., Carrière, I., de Mendonca, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007). The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology, 69(6), 536-45.
Ritchie K, et al. The Neuroprotective Effects of Caffeine: a Prospective Population Study (the Three City Study). Neurology. 2007 Aug 7;69(6):536-45. PubMed PMID: 17679672.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The neuroprotective effects of caffeine: a prospective population study (the Three City Study). AU - Ritchie,K, AU - Carrière,I, AU - de Mendonca,A, AU - Portet,F, AU - Dartigues,J F, AU - Rouaud,O, AU - Barberger-Gateau,P, AU - Ancelin,M L, PY - 2007/8/8/pubmed PY - 2007/8/31/medline PY - 2007/8/8/entrez SP - 536 EP - 45 JF - Neurology JO - Neurology VL - 69 IS - 6 N2 - OBJECTIVE: To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over. METHODS: Participants were 4,197 women and 2,820 men from a population-based cohort recruited from three French cities. Cognitive performance, clinical diagnosis of dementia, and caffeine consumption were evaluated at baseline and at 2 and 4 year follow-up. RESULTS: Caffeine consumption is associated with a wide range of sociodemographic, lifestyle, and clinical variables which may also affect cognitive decline. Multivariate mixed models and multivariate adjusted logistic regression indicated that women with high rates of caffeine consumption (over three cups per day) showed less decline in verbal retrieval (OR = 0.67, CI = 0.53, 0.85), and to a lesser extent in visuospatial memory (OR = 0.82, CI = 0.65, 1.03) over 4 years than women consuming one cup or less. The protective effect of caffeine was observed to increase with age (OR = 0.73, CI = 0.53, 1.02 in the age range 65 to 74; OR = 0.3, CI = 0.14, 0.63 in the range 80+). No relation was found between caffeine intake and cognitive decline in men. Caffeine consumption did not reduce dementia risk over 4 years. CONCLUSIONS: The psychostimulant properties of caffeine appear to reduce cognitive decline in women without dementia, especially at higher ages. Although no impact is observed on dementia incidence, further studies are required to ascertain whether caffeine may nonetheless be of potential use in prolonging the period of mild cognitive impairment in women prior to a diagnosis of dementia. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/17679672/The_neuroprotective_effects_of_caffeine:_a_prospective_population_study__the_Three_City_Study__ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=17679672 DB - PRIME DP - Unbound Medicine ER -